LIVE TECHNICAL SEMINAR
Share:

Nitrosamines After the Initial Assessment: When Does a Change Trigger Reassessment and How Should Impact Be Evaluated

  • Date
    30 - 31 July 2026
  • 11.00 AM Eastern Time (US/Canada)
    03.00 PM GMT

Course is now LIVE. Click below to join the session.

This course helps teams determine when lifecycle changes trigger nitrosamine reassessment, when testing is required, and how to justify control decisions using science-based rationale, purge assessment, CPCA principles, and global regulatory expectations.

/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }
REGISTRATION OPTIONS

Live session Plus
Complimentary 30 Days Streaming access

$390  |  One participant (viewer)

$490  |  Team (2 - 5 participants)

$590 |  Team (6 - 10 participants)

REGISTER FOR THE COURSE

US $390 per learner

30-Days Unlimited Streaming Access

/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }

REGISTER FOR THE COURSE

To Get 30-Day Access to ONLY this Course 

US $290 per learner
  • This course is Included in Subscription Pack
Subscription include access to entire Learning Library
/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }
  • Faculty
    G. Sundar
  • Duration
    2 Hours Each Day
  • Course ID
    TF3537
  • Live Q&A +
    Post-live Continued Learning
  • Presentation Handout
    & Templates
  • Assessment
    & Certification Included

 

Why take this course?

A nitrosamine risk assessment is often straightforward when the process, materials, suppliers, and product remain unchanged. The truly difficult decisions begin during lifecycle management when something changes. A new supplier is introduced. A reagent is replaced. A manufacturing site is transferred. A formulation is modified. An unexpected analytical result is reported. Teams must determine whether the existing risk assessment remains scientifically defensible or whether a formal reassessment, confirmatory testing, or additional control strategies are required.

This technical webinar focuses entirely on the critical decisions that follow post-approval change. Participants will learn how experienced pharmaceutical organizations evaluate reassessment triggers, determine the significance of supplier, process, formulation, and manufacturing modifications, and decide when physical testing is strictly warranted versus when a scientific rationale suffices. The session will deeply examine the application of ICH M7 purge assessments, the classification of Nitrosamine Drug Substance Related Impurities (NDSRIs) using CPCA principles, the justification of testing strategies, and the development of agile control approaches that remain fully compliant as products, processes, and international regulatory expectations continue to evolve.

Make Clear Reassessment Trigger Decisions to Strengthen Testing and Control Strategy Justification

Few life science organizations still struggle with the initial phase of identifying potential nitrosamine risks. The greater, ongoing operational challenge is determining exactly what to do after a change occurs. The same high-stakes question repeatedly surfaces across Change Control reviews, technical assessments, supplier evaluations, deviation investigations, Annual Product Reviews (APR) / Product Quality Reviews (PQR), and global regulatory submissions: Does this change require a nitrosamine reassessment?


The answer is rarely obvious or binary. Some lifecycle changes necessitate immediate confirmatory testing, revised specifications, or a comprehensive overhaul of the regulatory dossier. Others require only a highly robust, documented scientific rationale. This webinar demystifies how those decisions are made. Participants will review the exact technical factors used to evaluate change impact, understand when a purge-based justification can legally bypass laboratory analysis, and assess whether existing control strategies remain resilient. The session also directly addresses the latest NDSRI categorization matrix, specification limit decisions, evolving Acceptable Intake (AI) calculations, and the practical, harmonized application of current USFDA, EMA, Health Canada, ANVISA, and TGA expectations.

Key Areas Covered

  • Determine with scientific precision when a post-approval change triggers a mandatory, documented nitrosamine reassessment versus when the existing Step 1 assessment remains regulatory-defensible.
  • Evaluate the complex impact of supplier shifts, raw material variations, excipient nitrites/amines, process modifications, formulation adjustments, and manufacturing site transfers on overall nitrosamine risk profiles.
  • Assess whether laboratory confirmatory testing is legally necessary or whether a robust, data-driven scientific justification can independently support the change control.
  • Apply ICH M7 semi-quantitative purge scoring concepts to support change impact evaluations and justify the absence of routine downstream testing.
  • Distinguish minor lifecycle changes from material changes that fundamentally alter the thermodynamic or kinetic potential for nitrosamine formation.
  • Evaluate complex NDSRIs using current CPCA-based structural feature scoring when compound-specific rodent carcinogenicity data is unavailable.
  • Select and defend appropriate control strategies (e.g., Option 1–4 controls) based on process capability, process understanding, and available analytical limits of quantification (LOQ).
  • Build audit-ready, highly defensible reassessment rationales capable of seamlessly passing global regulatory reviews, health authority inspections, and annual PQR audits.

Who Must Attend

This technical training is custom-engineered for senior technical professionals, managers, and directors operating across the global life sciences space, specifically within:

  • Quality Assurance (QA) Departments
  • Regulatory Affairs (RA) & Regulatory CMC Departments
  • Quality Control (QC) & Analytical Development Departments
  • Process Chemistry & Technical Services Departments
  • Formulation Development Departments
  • Manufacturing Operations Departments
  • Supplier Quality Departments

Complete Course Agenda

MODULE 1

Determining When Nitrosamine Reassessment Should Be Initiated

  • The Regulatory Paradigm Shift: Moving from the initial deadlined mandates (Step 1 Risk Evaluation) into active, continuous Quality Risk Management (QRM) under ICH Q9(R1) and lifecycle management under ICH Q12.

  • Defining the "Trigger": Identifying the exact regulatory and technical boundaries where an existing risk assessment is rendered obsolete.

  • Regulatory Expectations Compared: Cross-evaluating current mandates from the USFDA, EMA (Article 5(3)), Health Canada, ANVISA, and TGA regarding post-marketing surveillance and immediate notification obligations upon discovering new risk paths.

  • The Chronological Reassessment Workflow: Establishing internal standard operating procedures (SOPs) that cleanly interface your Change Control management system with your Nitrosamine Core Team.

MODULE 2

Supplier Changes, Raw Material Changes, and Excipient Changes

  • The Risk of the Unseen: How changing an Active Pharmaceutical Ingredient (API) or Key Starting Material (KSM) supplier introduces hidden risks via altered synthetic routes, recovery processes, or recycled solvents.

  • Excipient-Driven Nitrosation: Evaluating the critical risk of micro-levels of inorganic nitrites ($NO_2^-$) in common excipients (e.g., microcrystalline cellulose, lactose, starch, povidone, crospovidone).

  • The Amine Component: Assessing secondary or tertiary amines present as structural elements, degradation products, or processing aids within the excipient matrix.

  • Supplier Qualification Strategy: Moving beyond the standard vendor Questionnaire — establishing proactive vendor-derived nitrite monitoring, mass balance calculations, and cross-contamination risk bounds for recovered materials.

MODULE 3

Supplier Changes, Raw Material Changes, and Excipient Changes

  • Altered Kinetics and Thermodynamics: How subtle modifications in reaction temperature, pH, hold times, and crystallization steps can dramatically favor or accelerate nitrosamine formation.

  • Reagents and Catalysts: Evaluating the direct introduction of nitrosating agents (e.g., $NaNO_2$, alkyl nitrites) or secondary/tertiary amines used as bases or phase-transfer catalysts (e.g., TEA, DIPEA, TBA).

  • The Solvent Dilemma: The severe risks associated with fresh vs. recovered/recycled solvents (e.g., DMF, DMAc, NMP) and the potential for cross-contamination in shared recovery infrastructure.

  • Azide Mitigation Pitfalls: Analyzing how steps taken to destroy residual azides using nitrous acid can inadvertently drive massive nitrosamine spikes if secondary or tertiary amines are present in the same chemical environment.

MODULE 4

Formulation Changes, Manufacturing Transfers, and Other Product Lifecycle Changes

  • Solid State vs. Liquid Phase Reactions: Evaluating how changing a formulation (e.g., switching from dry granulation to wet granulation) introduces moisture and local pH microenvironments that accelerate NDSRI formation during shelf life.

  • Primary Packaging Risks: Assessing the migration of nitrocellulose printing inks from lamination foils or the leaching of vulcanizing agents and secondary amines from rubber stoppers and lidding materials.

  • Manufacturing Site Transfers: Evaluating the impact of changes in equipment geometry, fluid bed dryer design, localized hotspots, and the risk of airborne or cleaning-validation-related cross-contamination in multi-product facilities.

  • Unexpected Analytical Stability Results: How to manage and investigate a sudden "Out of Specification" (OOS) or "Out of Trend" (OOT) nitrosamine result during ongoing stability programs for a previously validated product.

MODULE 5

Evaluating Change Impact and Establishing Reassessment Requirements

  • Risk Categorization Matrix: Constructing a highly effective, scannable technical framework to classify post-approval changes based on their chemical probability of driving nitrosation.

  • Scientific Rationale Development: Drafting the critical technical bridge between Change Control initiation and regulatory dossier variation submissions.

  • Impact of Acceptable Intake (AI) Shifts: How a newly published, lowered regulatory AI value for a specific nitrosamine automatically triggers a retroactive impact evaluation on existing, approved processes.

MODULE 6

Confirmatory Testing Versus Purge-Based Scientific Justification

  • When Testing is Non-Negotiable: Definitive regulatory thresholds (USFDA/EMA) that mandate immediate analytical verification (e.g., high-risk factors combined with lack of historical batch data).

  • ICH M7 Purge Factor Framework: Utilizing the semi-quantitative purge calculation tool to scientifically justify why laboratory testing is not required.

  • The Scoring Logic: Applying structural, reactivity, solubility, and volatility purge parameters to demonstrate that the process possesses an inherent, validated purging capacity 

  • Dossier Documentation: How to present a purge-based justification that successfully withstands aggressive scrutiny by EDQM or Health Canada reviewers without prompting formal deficiency letters.

MODULE 7

NDSRI Assessment and Application of CPCA Principles

  • The NDSRI Challenge: Understanding why Nitrosamine Drug Substance Related Impurities represent the single most complex challenge in modern pharmaceutical lifecycle management.

  • Carcinogenic Potency Categorization Approach (CPCA): A deep dive into the harmonized approach adopted by FDA, EMA, Health Canada, ANVISA, and TGA for predicting nitrosamine potency based on structural features.

  • The Step-by-Step CPCA Scoring System:
    1. Count of Hydrogen Atoms on the alpha-carbons.

    2. Deactivating Features: Presence of electron-withdrawing groups, carboxylic acids, or steric hindrance that decreases nitrosation/activation potential.

    3. Activating Features: Rings, chains, or specific structural additions that amplify mutagenic risk.

    4. Final Potency Category Assignment: Categorizing the molecule into Potency Category 1, 2, 3, 4, or 5, and automatically determining its corresponding Acceptable Intake (AI) limit (ranging from 26 ng/day to 1500 ng/day).

  • Surrogate Selection Criteria: Choosing highly accurate structural analogues when utilizing read-across approaches or enhanced Ames testing paradigms.

MODULE 8

Testing Strategies, Control Strategies, Mitigation Measures, and Ongoing Monitoring Expectations

  • The Analytical Armory: Selecting and validating ultra-sensitive methods including LC-MS/MS and GC-MS/MS featuring specialized Limits of Quantification (LOQ) capable of tracking parts-per-billion (ppb) concentrations.

  • ICH Q6A Control Options:
    • Option 1: Control testing in the finished product specification at or below the AI limit.

    • Option 2: Control testing in the API or intermediate specification at or below the AI limit.

    • Option 3: Control testing upstream with a validated, robust purge justification.

    • Option 4: Omission of routine testing based on clear process understanding and analytical results consistently staying below 10% of the AI limit.

  • Formulation Mitigation Engineering: Implementing proactive formulation barriers, such as adding antioxidants (e.g., Ascorbic Acid, Alpha-Tocopherol) or amino acids (e.g., L-Lysine, L-Arginine) to physically inhibit the inline formation of NDSRIs during shelf life.

  • Continuous Lifecycle Compliance: Integrating continuous monitoring expectations into your Annual Product Review (APR/PQR) to maintain absolute state-of-control compliance.

COURSE DIRECTOR

G. Sundar

G. Sundar is a quality practitioner with vast 35 years’ experience in the field of Quality Assurance, Quality Control, Bioequivalence and Pharmaceutical Regulations. His quality management experience covers the implementation of Quality tools in bulk drugs, formulation companies and CRO. He is an expert in Total Quality Systems as per GLP, GDP and as per EMEA, USFDA, MHRA and MCC, TGA, ANVISA, Japan guidelines. He has conducted more than 200 GMP/GLP audits including Q10 & Q11 implementation, 50 Formulation Contract Manufacturing Units (all types of formulations), 10 Contract Research and Analytical laboratories, 10 Clinical research CROs. He has also conducted 1000 plus trainings Asia, US, EU, Middle East and South-East Asia. Mr. Sundar Ganesan is the Director and Senior Consultant at PharmQA Compliance Services.

If you would like to request a Proforma invoice to sign up for this course. please click here

Commonly Asked Questions About This Subject

The following questions address practical regulatory, compliance, validation, quality, operational, and inspection-related considerations commonly associated with this subject.

How much evidence is enough to justify a root cause conclusion during a GMP investigation?

A root cause conclusion should be supported by evidence that directly links the identified cause to the observed event. Inspection concerns frequently arise when investigations move from suspicion to conclusion without demonstrating that connection. Statements such as "operator error," "lack of attention," or "procedure not followed" often raise additional questions rather than resolving them.


Reviewers typically look for objective support such as records, interviews, historical trends, process data, equipment performance, environmental conditions, or documented observations that point toward the same conclusion. A root cause becomes difficult to defend when equally plausible explanations were not evaluated or eliminated.


Rework commonly occurs when teams stop investigating after finding the first reasonable explanation. Experienced investigators continue until they can explain both how the failure occurred and why existing controls did not prevent it. The strongest investigations leave little ambiguity about why the selected root cause was chosen over competing possibilities and what evidence supports that decision.

Why do repeat deviations continue to occur even after CAPAs have been completed and closed?

An operational failure point appears when CAPA activities focus on correcting the immediate event while leaving the conditions that enabled it untouched. The deviation may disappear temporarily, yet the underlying system remains unchanged.


A review of recurring events often reveals that training was repeated, procedures were revised, or reminders were issued. Those actions may address symptoms without addressing workload pressures, process complexity, unclear responsibilities, equipment limitations, conflicting procedures, weak oversight, or ineffective management controls.


Inspection friction develops when the same event reappears under slightly different circumstances and prior CAPA records show closure without meaningful system improvement. Investigators frequently discover that effectiveness checks only confirmed short-term compliance rather than sustained performance.


Evidence that carries weight includes measurable process improvement, reduction in recurrence rates, control enhancements, revised workflows, resource adjustments, and objective performance monitoring. Sustainable CAPA outcomes are usually associated with changes to the system rather than changes to individual behavior alone.

When is it appropriate to close an investigation without identifying a definitive root cause?

A definitive root cause is not always obtainable, particularly when evidence has been lost, the event cannot be reproduced, or multiple contributing factors remain equally plausible. What becomes difficult to defend is closing the investigation with uncertainty while treating the issue as fully resolved.


Experienced reviewers generally accept that some investigations end with a probable cause rather than a confirmed root cause. Their focus shifts to whether the investigation was thorough, whether alternative explanations were considered, and whether risk was managed appropriately despite the remaining uncertainty.


Documentation often weakens when teams simply state that the root cause could not be determined. Stronger records explain what evidence was reviewed, what investigative paths were pursued, why additional conclusions could not be supported, and how residual risk will be controlled.


Inspection discussions tend to be far more productive when uncertainty is acknowledged and managed than when unsupported certainty is documented simply to satisfy a procedural expectation.

What distinguishes a strong management review of investigations from a routine approval signature?

A governance concern emerges when management approval becomes a documentation checkpoint rather than an evaluation of investigation quality. Inspectors frequently recognize the difference within minutes of reviewing investigation files.


Strong management oversight focuses on the logic behind conclusions, adequacy of evidence, quality of impact assessments, recurring trends, implementation barriers, and the long-term effectiveness of proposed actions. Questions are raised, assumptions are challenged, and gaps are addressed before closure.


Routine approvals often leave obvious weaknesses untouched. Investigations may contain broad conclusions, incomplete impact evaluations, weak effectiveness measures, or corrective actions that cannot reasonably prevent recurrence. Yet the file carries multiple approval signatures.


Records that demonstrate meaningful management involvement often contain documented comments, requests for additional analysis, escalations, trend reviews, resource decisions, and evidence that leadership evaluated business and quality implications. Those records show active ownership of the process rather than administrative participation.

Your TalkFDA Webinar Experience

When you reserve your seat, everything is organized for you — from access to certification from one place.

1. Confirmation

You receive a confirmation email and your course appears instantly in your TalkFDA dashboard.

2. Your Course Hub
Your TalkFDA course page becomes your central hub where you can join the session, access materials, and manage your learning.

3. Join the Live Training
At the scheduled time, click Join Session and you’ll be connected to the live Webex session with the instructor.

4. Watch Again Anytime
After the session, the playback becomes available on the same course page so you can revisit important sections.
5. Earn Your Certificate
Complete the course and your certificate is unlocked automatically in your learning history.

Everything related to your webinar: access, materials, playback, and certification — lives in one place.
Simple. Organized. Professional.
Go ahead and reserve your seat with confidence.

Built on 20+ years of global regulatory training experience across FDA, EMA, MHRA, and ICH frameworks.
Trusted by professionals across 80+ countries.

Testimonials

This is an upcoming session. Feedback below reflects experiences from similar programs delivered by our expert faculty.

“Session was easy to follow even for non-core team members. That helped.”
- Production Officer
“Good balance. Not too basic, not too deep. Worked well for mixed team.”
- Manager, Regulatory Affairs
“Team found it useful. Especially for aligning understanding across functions.”
- Director, Operations

Ready to Strengthen Your Team? Let’s Build Your Training Plan.

Whether you’re looking for a single onsite workshop or a multi-team training series, we’ll help you design a program that fits your goals, timelines, and operational reality.

Your team deserves the clarity.
Your organization deserves the confidence.

Upcoming Courses

Featured Courses